Q32 Bio Advances Bempikibart After Positive Phase 2 Data
Q32 Bio reported positive 36-week topline data from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata.Bempikibart is a fully human anti-IL-7Rα monoclonal…
